Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBX4UJ)

Drug Name
4-nitrophenyl phosphate Drug Info
Synonyms
4-nitrophenyl phosphate; 4-Nitrophenyl dihydrogen phosphate; 330-13-2; Nitrophenylphosphate; Phosphoric acid, mono(4-nitrophenyl) ester; p-nitrophenyl phosphate; p-Nitrophenyl dihydrogen phosphate; p-Nitrophenol phosphate; p-Nitrophenylphosphate; (4-nitrophenyl) dihydrogen phosphate; PNPP; NSC 404086; Phenol, p-nitro-, dihydrogen phosphate; CHEMBL24231; (4-nitrophenoxy)phosphonic acid; CHEBI:17440; XZKIHKMTEMTJQX-UHFFFAOYSA-N; pNPP Alkaline Phosphatase Substrate; Phosphoric acid, mono(p-nitrophenyl) ester (8CI); Phosphoric ac
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
378
ChEBI ID
CHEBI:17440
CAS Number
CAS 330-13-2
TTD Drug ID
DMBX4UJ
INTEDE Drug ID
DR2064

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Carbonic anhydrase I (CA-I)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [6]
Ethoxzolamide DMVO4ED Glaucoma/ocular hypertension 9C61 Approved [7]
Dichlorphenamide DMH7IDQ Chronic glaucoma 9C61.0Z Approved [7]
Methazolamide DM7J2TA Glaucoma/ocular hypertension 9C61 Approved [8]
Acetazolamide DM1AF5U Absence epilepsy Approved [7]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [9]
PARABEN DMEW5Z8 N. A. N. A. Phase 3 [10]
CG-100649 DMIKMA9 Arthritis FA20 Phase 3 [11]
PHENOL DM1QSM3 N. A. N. A. Phase 2/3 [9]
Coumate DMVKW0N Breast cancer 2C60-2C65 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Carbonic anhydrase II (CA-II)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [6]
Sulfamylon DMIO1K0 Bacterial infection 1A00-1C4Z Approved [13]
Dorzolamide DMA17D0 Ocular hypertension 9C61.01 Approved [14]
Chlorothiazide DMLHESP Chronic heart failure BD1Z Approved [15]
Ethoxzolamide DMVO4ED Glaucoma/ocular hypertension 9C61 Approved [16]
Dichlorphenamide DMH7IDQ Chronic glaucoma 9C61.0Z Approved [16]
Cyclothiazide DMJ4AWC Congestive heart failure BD10 Approved [17]
Ethinamate DMK57GB Insomnia 7A00-7A0Z Approved [18]
Benzthiazide DMQWZ0H High blood pressure BA00 Approved [19]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Carbonic anhydrase (CA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [20]
Sulfamylon DMIO1K0 Bacterial infection 1A00-1C4Z Approved [21]
Quinethazone DMWCOSR Hypertension BA00-BA04 Approved [22]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [9]
PARABEN DMEW5Z8 N. A. N. A. Phase 3 [10]
PHENOL DM1QSM3 N. A. N. A. Phase 2/3 [9]
Coumate DMVKW0N Breast cancer 2C60-2C65 Phase 2 [12]
SULFAMIDE DMMAS3K N. A. N. A. Phase 1 [23]
FERULIC ACID DMJC7NF Discovery agent N.A. Patented [10]
PMID30074415-Compound-21 DM3NPOU N. A. N. A. Patented [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tyrosine-protein phosphatase non-receptor type 1 (PTPN1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [25]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [26]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [27]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [28]
Benzoic Acid DMKB9FI Alopecia areata ED70.2 Approved [5]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [29]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [30]
Seocalcitol DMKL9QO Rickets 5B57 Phase 3 [31]
URSOLIC ACID DM4SOAW Metabolic syndrome x 5C50-5D2Z Phase 2 [32]
DNCB DMDTVYC Immune System disease 4A01-4B41 Phase 2 [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Dual specificity protein phosphatase 23 (DUSP23)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [27]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [34]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [35]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [36]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [37]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [38]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Affected By Low molecular weight phosphotyrosine protein phosphatase (ACP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [39]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [40]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [41]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [28]
Benzoic Acid DMKB9FI Alopecia areata ED70.2 Approved [5]
Aminoglutethimide DMWFHMZ Cushing disease 5A70 Approved [42]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [43]
Vinblastine DM5TVS3 Advanced cancer 2A00-2F9Z Approved [44]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [44]
Tocopherol DMBIJZ6 N. A. N. A. Phase 2 [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tyrosine-protein phosphatase non-receptor type 2 (PTPN2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [45]
Acocantherin DM7JT24 Atrial fibrillation BC81.3 Approved [46]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [47]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [41]
Benzoic Acid DMKB9FI Alopecia areata ED70.2 Approved [5]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [48]
Diphenylpyraline DMW4X37 Allergic rhinitis CA08.0 Approved [49]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [50]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [38]
PMID28870136-Compound-48 DMPIM9L N. A. N. A. Patented [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Alkaline phosphatase, placental type (ALPP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lidocaine DML4ZOT Anaesthesia 9A78.6 Approved [51]
Paricalcitol DMYBV3G Hyperparathyroidism 5A51 Approved [51]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [52]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [53]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [54]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [55]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [41]
Isoproterenol DMK7MEY Atrioventricular block Approved [56]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [57]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [58]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carbonic anhydrase (CA) TTUNARX NOUNIPROTAC Inhibitor [1]
Carbonic anhydrase I (CA-I) TTHQPL7 CAH1_HUMAN Inhibitor [1]
Carbonic anhydrase II (CA-II) TTANPDJ CAH2_HUMAN Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Tyrosine-protein phosphatase non-receptor 1 (PTP1B) Main DME DE6TFXV PTN1_HUMAN Substrate [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alkaline phosphatase, placental type (ALPP) OTZU4G9W PPB1_HUMAN Biotransformations [3]
Dual specificity protein phosphatase 23 (DUSP23) OTE2PG54 DUS23_HUMAN Biotransformations [4]
Low molecular weight phosphotyrosine protein phosphatase (ACP1) OTJ9CKLU PPAC_HUMAN Biotransformations [5]
Tyrosine-protein phosphatase non-receptor type 1 (PTPN1) OTO4ZVIA PTN1_HUMAN Biotransformations [5]
Tyrosine-protein phosphatase non-receptor type 2 (PTPN2) OTV4VJGE PTN2_HUMAN Biotransformations [5]

References

1 Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12.
2 Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding. J Biol Chem. 2006 Feb 24;281(8):5258-66.
3 The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs. Pharm Res. 1992 Apr;9(4):497-503. doi: 10.1023/a:1015840329786.
4 Molecular cloning and characterization of a novel dual-specificity phosphatase 23 gene from human fetal brain. Int J Biochem Cell Biol. 2004 Aug;36(8):1542-53. doi: 10.1016/j.biocel.2003.12.014.
5 Synthesis, biological activity and structure-activity relationships of new benzoic acid-based protein tyrosine phosphatase inhibitors endowed with insulinomimetic effects in mouse C2C12 skeletal muscle cells. Eur J Med Chem. 2014 Jan;71:112-27. doi: 10.1016/j.ejmech.2013.11.001. Epub 2013 Nov 11.
6 Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
9 Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
10 Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
11 Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
12 Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
13 Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
14 Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
15 Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
16 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17 Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
18 Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
19 Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
20 Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
21 Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
22 Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
23 Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
24 Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
25 Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
26 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
27 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
28 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
29 Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
30 Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling. Neurotoxicology. 2015 Sep;50:56-70.
31 Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
32 Coumarins from Angelica decursiva inhibit -glucosidase activity and protein tyrosine phosphatase 1B. Chem Biol Interact. 2016 May 25;252:93-101. doi: 10.1016/j.cbi.2016.04.020. Epub 2016 Apr 13.
33 Proteomic analysis of the cellular response to a potent sensitiser unveils the dynamics of haptenation in living cells. Toxicology. 2020 Dec 1;445:152603. doi: 10.1016/j.tox.2020.152603. Epub 2020 Sep 28.
34 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
35 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
36 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
37 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
38 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
39 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
40 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
41 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
42 Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
43 Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy. 2010 Aug;6(6):711-24. doi: 10.4161/auto.6.6.12397. Epub 2010 Aug 17.
44 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
45 Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
46 Ouabain at pathological concentrations might induce damage in human vascular endothelial cells. Acta Pharmacol Sin. 2006 Feb;27(2):165-72. doi: 10.1111/j.1745-7254.2006.00244.x.
47 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
48 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
49 Controlled diesel exhaust and allergen coexposure modulates microRNA and gene expression in humans: Effects on inflammatory lung markers. J Allergy Clin Immunol. 2016 Dec;138(6):1690-1700. doi: 10.1016/j.jaci.2016.02.038. Epub 2016 Apr 24.
50 Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
51 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
52 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
53 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
54 Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
55 The psychoactive compound of Cannabis sativa, (9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 2015 Aug 6;334:94-103. doi: 10.1016/j.tox.2015.06.005. Epub 2015 Jun 9.
56 The effects of desmethylimipramine on cyclic AMP-stimulated gene transcription in a model cell system. Biochem Pharmacol. 2005 Sep 1;70(5):762-9. doi: 10.1016/j.bcp.2005.06.012.
57 The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
58 Ornithine decarboxylase antizyme upregulates DNA-dependent protein kinase and enhances the nonhomologous end-joining repair of DNA double-strand breaks in human oral cancer cells. Biochemistry. 2007 Aug 7;46(31):8920-32. doi: 10.1021/bi7000328. Epub 2007 Jul 14.